Finally, although our dataset represents a relatively recent cohort for whom most of the contemporary adjuvant treatment options are provided, there are some novel therapeutic options that were not available, such as CDK4/6 inhibitors or pertuzumab.16,33 The implication of these recently developed therapeutic options in breast cancer with distant metastasis should be further explored in the future. Here, CDK4 is linked to breast carcinoma.